ACAD

In the past six months, ACADIA's stock price has decreased by 0.75%, but has increased by 32.31% over the past year. ACADIA reported Q1 2026 earnings per share of $0.02, missing estimates, and total revenues were $268.1 million, also missing estimates. The successful launch of DAYBUE STIX was highlighted. The company reaffirmed its full-year 2026 revenue guidance of $1.22 billion to $1.28 billion. Selling, general, and administrative expenses rose significantly. Upcoming Phase 2 topline data for remlifanserin and Phase 3 data for trofinetide in Japan are considered significant near-term catalysts.